INGALLS & SNYDER LLC 13D and 13G filings for Corcept Therapeutics Incorporated:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-21 5:23 pm Sale | 2024-12-31 | 13G | Corcept Therapeutics Incorporated CORT | INGALLS & SNYDER LLC | 8,173,721 7.800% | -88,755 (-1.07%) | Filing |
| 2024-03-27 2:32 pm Purchase | 2023-12-31 | 13G | Corcept Therapeutics Incorporated CORT | INGALLS & SNYDER LLC | 8,262,476 8.000% | 1,172,106 (+16.53%) | Filing |
| 2023-02-17 4:59 pm Purchase | 2022-12-31 | 13G | Corcept Therapeutics Incorporated CORT | INGALLS & SNYDER LLC | 7,090,370 6.600% | 434,393 (+6.53%) | Filing |
| 2022-02-04 07:11 am Sale | 2021-12-31 | 13G | Corcept Therapeutics Incorporated CORT | INGALLS & SNYDER LLC | 6,655,977 5.700% | -927,795 (-12.23%) | Filing |
| 2021-02-09 4:44 pm Sale | 2020-12-31 | 13G | Corcept Therapeutics Incorporated CORT | INGALLS & SNYDER LLC | 7,583,772 6.530% | -702,158 (-8.47%) | Filing |